Hexima Ltd (hxl) Logo

Hexima Ltd (HXL)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

HXL Chart

HXL's Principal Activity is the research and development of plant-derived proteins and peptides for applications as human therapeutics.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -43.23%

Size

Market Capitalisation
ASX Rank 1,687 of 2,237
Sector Rank

Key Information

Shares Issued
Sector Healthcare
Similar Companies -
EPS $0.00
DPS $0.00
NTA per share $0.00

Broker Consensus

HXL is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

Hexima Limited (HXL) is a biotechnology company actively engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting a 132 patient Australian phase IIb clinical trial of HXP124 for onychomycosis.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office La Trobe University VIC 3086
Website www.hexima.com.au
Registry Link Market Services
Auditor KPMG
Date Listed 1 Dec 2020

Upcoming Calendar

Date Event
24/02/2022 Report (Interim)

Dividend History

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Steven Michael Skala Alternate Director Mar 2020 Director Bio icon

Mr Steven Michael Skala

Alternate Director

Mr Skala is Vice Chairman, Australia and New Zealand of Deutsche Bank AG. He retired from legal practice after almost 25 years experience in commercial law. Between 1985 and 2004 he was a partner of law firm, Arnold Bloch Leibler, and was Head of its Corporate and Commercial Practice for several years. He is a Director of the Australian Broadcasting Corporation, Deutsche Australia Limited, Wilson HTM Investment Group Limited, and The Centre for Independent Studies and he is Deputy Chairman of the General Sir John Monash Foundation. He is also Vice President of The Walter and Eliza Hall Institute for Medical Research and was previously Chairman of Film Australia Limited and The Australian Centre for Contemporary Arts and a director of Max Capital Group Limited and The Australian Ballet.

Mr Michael Douglas Aldridge Chief Executive Officer,Managing Director May 2019 Director Bio icon

Mr Michael Douglas Aldridge

Chief Executive Officer,Managing Director

Mr Aldridge most recently served as Senior Vice President, Corporate & Strategic Development of Codexis from October 2016 until August 2018. Prior to that, from January 2012 to September 2014, he served as Senior Vice President, Corporate Strategic Development for Questcor Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company acquired by Mallinckrodt Pharmaceuticals in 2014. From May 2010 to September 2012, Mr Aldridge served as Chief Executive Officer and a member of the board of directors for Xenome Limited, a privately-held biopharmaceutical company headquartered in Australia. Between 2003 and 2009, he served as Chief Executive Officer and a member of the board of directors and a strategic consultant of Peplin, Inc., a publicly-traded drug development company acquired by LEO Pharma A/S in 2009. Prior to that, he held investment banking positions at various financial firms, including Wilson HTM Investment Group, Bear, Stearns & Co., Volpe, Brown, Whelan & Company and S.G. Warburg Group.

Mr Scott Christian Robertson Non-Executive Director Nov 2018 Director Bio icon

Mr Scott Christian Robertson

Non-Executive Director

Mr Robertson is currently Chief Financial Officer at DiCE Molecules. Prior to DiCE Molecules, he served at DuPont where he was Business Development Director for DuPont Pioneer with responsibility for the business unit's crop genetics and precision agriculture M&A activity. He also held the position of portfolio manager with DuPont Ventures where he focused on strategic investment opportunities in production agriculture and the intersection of agriculture and downstream renewable technologies. Prior to joining DuPont, he was an investment professional at MPM Capital, a life sciences-dedicated venture capital fund, and before that a member of the Healthcare Investment Banking groups at Merrill Lynch & Co. and Thomas Weisel Partners. He is also a member of Risk Committee.

Mr Justin Zhen Nan Yap Non-Executive Director Jul 2018 Director Bio icon

Mr Justin Zhen Nan Yap

Non-Executive Director

Mr Yap is a Non-Executive Director of CathRx Limited, an Australian medical device company commercialising cardiac electrophysiology catheters for the treatment of heart rhythm disorders. He is a Non-Executive Director of Wilhelm Integrated Solutions Pty Ltd, a distributor of integrated operating room technology to hospitals around Australia. Prior to this, he began his career in investment banking for Mosaic Risk Management Pty Ltd, a wholly owned subsidiary of Wilson HTM Limited specialising in derivatives risk management. He s also a member of Risk Committee.

Dr Nicole Louise van der Weerden Chief Operating Officer,Executive Director Dec 2014 Director Bio icon

Dr Nicole Louise van der Weerden

Chief Operating Officer,Executive Director

Dr van der Weerden has experience as she has led the gene discovery program for the Pioneer partnership on control of fungal diseases in corn. She led the Hexima team that identified the clinical opportunities for plant antifungal molecules and discovered and developed HXP124 for treatment of onychomycosis. He is also an inventor on nine patent applications. Her PhD research on the antifungal properties and mechanism of action of plant defensins led to the award of a prestigious Victoria Fellowship in 2006.

Professor Marilyn Ann Anderson Chief Science Officer,Executive Director Nov 2010 Director Bio icon

Professor Marilyn Ann Anderson

Chief Science Officer,Executive Director

Professor Anderson has over 40 years of experience in scientific research in the area of biochemistry and genetics. After completing a BSc Honours at The University of Melbourne and a PhD in Biochemistry at La Trobe University, Professor Anderson spent seven years in the United States working on diabetes at the University of Miami Florida, and molecular biology at Cold Spring Harbor Laboratory NY. She is an expert on antifungal and insecticidal molecules produced by plants. She is a Professor of Biochemistry at La Trobe University, and a member of the Australian Academy of Science Council. She was appointed an Officer of the Order of Australia in 2016 for distinguished service to science and higher education. She was a member of the La Trobe Council until 2017.

Professor Jonathan Paul West Non-Executive Director,Non-Executive Chairman Nov 2005 Director Bio icon

Professor Jonathan Paul West

Non-Executive Director,Non-Executive Chairman

Professor West was the founding Director of the Australian Innovation Research Centre. Prior to that, he taught for 18 years at the Harvard University Graduate School of Business Administration, where he was Associate Professor, founding Director of the Harvard University Life Sciences Initiative, and from 1998-1999 the Novartis Faculty Research Fellow. He has been Visiting Professor at Hitotsubashi University and the Nomura School of Advanced Management in Tokyo, Japan and Visiting Professor at the University de Paris IX-Dauphine, Sorbonne. Professor West was Chairman of the Asia Advisory Council of Bunge Ltd and has served as an advisor to other corporations and several Governments around the world, including in the life sciences field DuPont, Roche, Novartis, Syngenta and the J.R. Simplot Company, along with the Governments of Singapore, Japan, Hong Kong and France. He was a member of the Scientific Advisory Board of the Novartis Agricultural Discovery Institute in La Jolla, California. In Australia, he has served on the Prime Minister's Science, Engineering, Innovation Council's Working Group on Science and Technology in China and India and in 2006 was 'Eminent Thinker in Residence' with the Premier of NSW. Professor West is the non-executive chairman of Gowing Bros Limited and non-executive director of Boundary Bend Limited and the Hydration Pharmaceuticals Company Limited. He is also the Chairman of Risk committee.

Ms Helen Molloy Company Secretary,Finance Controller N/A
Marilyn A Anderson Chief Science Officer N/A
Robyn L Heath Senior Vice President Product Development N/A

Director Interests

The current holdings of HXL directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Steven Skala 10/03/2020 4,167,467 5,480,029 125,000 N/A
Michael Aldridge 21/05/2019 N/A N/A 2,750,000 N/A
Scott Robertson 21/11/2018 N/A N/A 312,500 N/A
Justin Yap 17/07/2018 N/A N/A 312,500 N/A
Nicole van der Weerden 16/12/2014 144,700 N/A 1,650,000 N/A
Marilyn Anderson 23/11/2010 2,280,548 N/A 250,000 N/A
Jonathan West 27/08/2010 2,000,000 N/A N/A N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Nov 20, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Dato Lim Sen Yap 14,715,790 11.25%
Caroline House Superannuation Fund Pty Ltd (Caroline House S/F A/C) 8,287,131 6.33%
Woobinda Nominees Pty Ltd (The Woobinda Family A/C) 6,372,222 4.87%
Beta Gamma Pty Ltd (Walsh Street Super Fund A/C) 5,736,586 4.38%
Gowing Bros Limited 4,256,176 3.25%
Paul Orlin 3,750,000 2.87%
Gowing Bros Ltd 3,667,131 2.80%
HSBC Custody Nominees (Australia) Limited 3,496,219 2.67%
Balmoral Financial Investments Pty Ltd 3,051,090 2.33%
Adrienne Clarke 3,028,938 2.31%
Hugh Morgan 2,977,252 2.28%
Dalit Pty Ltd (Dalit Family A/C) 2,500,000 1.91%
Dongrisha Pty Ltd (The Dongrisha Investment A/C) 2,500,000 1.91%
Huysmans Pty Ltd (The Lama A/C) 2,346,011 1.79%
Marilyn Anderson 2,280,548 1.74%
Saxum Pty Ltd 2,106,755 1.61%
Cranley Nominees Pty Ltd (Fitzroy Family A/C) 2,007,674 1.53%
Pioneer Hi-Bred International Inc. 2,000,000 1.53%
Andama Holdings Pty Ltd (J & M Barlow Pension A/C) 1,851,057 1.41%
Mr Leon Francis Lachal & Mrs Susan Margaret Lachal (The Lachal Super Fund A/C) 1,779,249 1.36%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 72 198 158 392 105 925

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Skala, Steven Michael 05/10/2010 4,167,467 5.14
Clarke, Adrienne Elizabeth 05/10/2010 5,417,919 6.68
G F Dan O Brien 05/10/2010 5,000,000 6.17
Oatley, Robert Ian 05/10/2010 6,102,180 7.53
Morgan, Hugh Matheson 05/10/2010 6,454,503 7.96
Clianth Pty Limited 05/10/2010 4,213,510 5.20

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
Page Icon
HXL Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.